Type 2 diabetes patients who took daily doses of empagliflozin as an add-on to metformin/sulfonylurea treatment attained greater reductions in A1C at six months than those in the placebo group, according to a study in Diabetes Care. Greater weight loss and improved systolic blood pressure were also seen in the empagliflozin arm compared with the control group, researchers noted.

Related Summaries